Overview

A First-in-Human Study of QY211 Gel in Adult Subjects

Status:
Recruiting
Trial end date:
2024-10-23
Target enrollment:
Participant gender:
Summary
This is a phase Ia/Ib,Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Single and Multiple Topical Doses of QY211 Gel in Healthy Chinese Subjects and Patients with Mild to Moderate Atopic Dermatitis
Phase:
Phase 1
Details
Lead Sponsor:
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.